VNT-101 

VNT-101 is an orally active influenza A (IAV) inhibitor. VNT-101 disrupts NP-NP PPI to block NP oligomerization and destabilize the viral ribonucleoprotein (RNP) complex, with potent antiviral activity across multiple influenza A subtypes. VNT-101 exhibits EC₅₀ values of 4-5 nM in cellular cytopathic effect (CPE) assay, 4-8 nM in neuraminidase (NA) assay, and 21-45 nM in RNP assay. VNT-101 demonstrates robust in vivo antiviral efficacy in mice infected with lethal H1N1 virus. VNT-101 can be used for the study of influenza A infection^[1].

VNT-101 exhibits potent anti-influenza A virus activity in RNP assay, with EC₅₀ = 45 nM against H1N1/California subtype and EC₅₀ = 21 nM against H3N2/Alaska subtype^[1].
VNT-101 shows strong inhibitory effect on viral neuraminidase in NA assay, with EC₅₀ = 8 nM against H1N1/PR8 subtype and EC₅₀ = 4 nM against H3N2/Alaska subtype^[1].
VNT-101 effectively suppresses virus-induced cytopathic effect in CPE assay, with EC₅₀ = 5 nM against H1N1/PR8 subtype and EC₅₀ = 4 nM against H3N2/Alaska subtype^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

VNT-101 (1-30 mg/kg, oral administration, twice daily for 5 days) exerts anti-influenza effect in Balb/c mice infected with H1N1 virus^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

456.41

C₂₁H₂₃F₃N₂O₆

2894060-67-2

COC[C@]1(COC[C@H](O1)COC2=CC=C(C(C=C3C(N)=O)=C(C(F)(F)F)NC3=O)C=C2)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Taft BR, et al. Discovery and Optimization of a Novel Series of Influenza A Virus Replication Inhibitors Targeting the Nucleoprotein Protein-Protein Interaction. J Med Chem. 2025 Aug 14;68(15):16349-16370.  [Content Brief]